Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, et al.
Genes & Diseases (2022) Vol. 10, Iss. 4, pp. 1318-1350
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling
Mingyao Huang, Xiaoqin Yu, Qing Wang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation
Xuran Zhang, Ke An, Xin Ge, et al.
Breast Cancer Research (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 7
BLM knockdown promotes cells autophagy via p53-AMPK-mTOR pathway in triple negative breast cancer cells
Lin Wang, Yanyan Wang, Chunchun Chen, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025), pp. 155864-155864
Closed Access
PD-1/PD-L1 axis induced host immunosuppression via PI3K/Akt/mTOR signalling pathway in piglets infected by Glaesserella Parasuis
Jingyang Li, Siyu Liu, Qiaoli Dong, et al.
BMC Veterinary Research (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 5
Dual inhibition of JAK3 and PD-L1 boosts immune response in triple negative breast cancer
Huali Xiang, Binfeng Tu, Xin Feng, et al.
Anti-Cancer Drugs (2025)
Closed Access
Mechanistic exploration of Traditional Chinese Medicine regulation on tumor immune microenvironment in the treatment of triple-negative breast cancer: based on CiteSpace and bioinformatics analysis
Dandan Feng, Dongqing Pu, Juan Ren, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Application of Gene Editing in Triple‐Negative Breast Cancer Research
Shuying Feng, Jixia Li, Aifen Yan, et al.
Cell Biochemistry and Function (2025) Vol. 43, Iss. 1
Closed Access
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Ibrahim S. Alalhareth, Saleh M. Alyami, Abdulrhman Alshareef, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 207-207
Open Access
Novel NIR-Ⅱ-Activated titanate-supported iridium nanoplatform delivers multimodal antitumor therapy synergistic with PD-1 inhibition in TNBC
Peixin Du, Xian Jiang, Zihan Xu, et al.
Chemical Engineering Journal (2025), pp. 160659-160659
Closed Access
Harnessing Artificial Intelligence for Precision Diagnosis and Treatment of Triple Negative Breast Cancer
Md Sadique Hussain, Prasanna Srinivasan Ramalingam, Gayathri Chellasamy, et al.
Clinical Breast Cancer (2025)
Closed Access
Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor‐Associated Macrophages to Potentiate Cancer Immunotherapy
Caiju Zhang, Jia‐Mi Li, Dan Xu, et al.
Advanced Science (2024) Vol. 11, Iss. 38
Open Access | Times Cited: 4
GBM immunotherapy: Exploring molecular and clinical frontiers
Mrinal K. Ghosh, Sunny Kumar, Sabana Begam, et al.
Life Sciences (2024) Vol. 356, pp. 123018-123018
Closed Access | Times Cited: 4
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery
Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al.
Genes & Diseases (2023) Vol. 10, Iss. 4, pp. 1402-1428
Open Access | Times Cited: 11
COVID‐19: Clinical status of vaccine development to date
Sunny Kumar, Malini Basu, Pratyasha Ghosh, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 1, pp. 114-149
Open Access | Times Cited: 16
A codelivery system loaded with PDL1-siRNA and sorafenib enhances the therapeutic effect of sorafenib on hepatocellular carcinoma via TAT-poly-SS-lysine modified chitosan
Yanan Chen, Zhonghao Jiang, Yan Zhuo, et al.
International Journal of Biological Macromolecules (2024) Vol. 263, pp. 130162-130162
Closed Access | Times Cited: 2
Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles
Wen Zhang, Yi­hui Zhai, Ying Cai, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3218-3231
Open Access | Times Cited: 2
New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway
Jiawei Yin, Peng Ren
Journal of Cancer Research and Therapeutics (2024) Vol. 20, Iss. 2, pp. 522-530
Open Access | Times Cited: 2
Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer
Yun Hu, Yan Li, Zhangcheng Yao, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 563-563
Open Access | Times Cited: 7
Covid-19 And Cancer: Insights Into Their Association And Influence On Genetic And Epigenetic Landscape
Mrinal K. Ghosh, Sunny Kumar, Kirat Kumar Ganguly, et al.
Epigenomics (2023) Vol. 15, Iss. 4, pp. 227-248
Open Access | Times Cited: 7
An exosome-based specific transcriptomic signature for profiling regulation patterns and modifying tumor immune microenvironment infiltration in triple-negative breast cancer
Han Wang, Ruo Wang, Lei Luo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Mahmood Araghi, Farshad Gharebakhshi, Fatemeh Faramarzi, et al.
Current Gene Therapy (2024) Vol. 25, Iss. 1, pp. 72-88
Closed Access | Times Cited: 1
Distinct genomic and immunologic tumor evolution in germlineTP53-driven breast cancers
Nabamita Boruah, David Hoyos, Renyta Moses, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Comprehensive analysis of PPP4C’s impact on prognosis, immune microenvironment, and immunotherapy response in lung adenocarcinoma using single-cell sequencing and multi-omics
Kaiyu Wang, Bo Peng, Ran Xu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
An overview of Skp2: a promising new therapeutic target of psoriasis
Yashika Tomar, Moushumi Baidya, Jay Chadokiya, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 8, pp. 689-700
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top